Danielle Haradon
0009-0006-2613-3866
Dana-Farber Cancer Institute
1 paper found
Refreshing results…
Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors
Missing publications? Search for publications with a matching author name.